SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
SAB highlights results from GLP toxicology study confirming SAB-142s mechanism of action at the 23rd Federation of Clinical Immunology Societies Study shows SAB’s fully-human multi-target... | June 21, 2023
United States Alexandra Kropotova Biotherapeutics Inc Exchange Commission Federation Of Clinical Immunology Societies Drug Administration
Source: marketscreener.com